On Jul. 29, 2020, Constant Therapeutics announced that its peptide drug TXA127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7), was planned for testing in a Phase 2 clinical trial at Columbia University Irving Medical Center in New York, New York.

The double-blind, placebo-controlled trial recruited 100 patients with COVID-19 who require oxygen but are not in the ICU. The endpoints include incidence of renal failure and incidence of respiratory failure.